Document Detail

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
MedLine Citation:
PMID:  19007987     Owner:  NLM     Status:  MEDLINE    
Acute myelogenous leukemia (AML) patients (24 consecutive patients, median age 71 years, 17 high-risk disease) were treated with all-trans retinoic acid, theophylline and valproic acid. Among 22 evaluable patients 9 responded with increased normal peripheral blood cell counts. The responses could be classified as hematological improvement according to response criteria for patients with myelodysplastic syndromes (MDS) for four patients only. The nine patients with increased normal cell counts had a median survival from start of therapy of 147 days compared with 48 days for the other patients. Four patients fulfilling the MDS criteria had a survival ranging from 112 to 644 days. The treatment was associated with decreased in vitro cytokine-dependent AML cell proliferation and increased blood levels of Endocan and angiopoietin-2 both for responders and non-responders. We conclude that the therapy causes disease stabilization for a subset of AML patients.
Anita Ryningen; Camilla Stapnes; Philippe Lassalle; Matthias Corbascio; Bjørn-Tore Gjertsen; Oystein Bruserud
Related Documents :
18711657 - Expression of mrp1 gene in acute leukemia.
16738077 - Depression and obstructive sleep apnea in patients with coronary heart disease.
2615527 - Coexistent chronic lymphocytic leukemia and polycythemia vera requiring no treatment.
20799577 - Ambiguous genitalia in neonates: a 4-year prospective study in a localized area.
3489367 - Radiographic efficacy in gastric ulcer: comparison of single-contrast and multiphasic e...
686857 - Joint hypermobility leading to osteoarthrosis and chondrocalcinosis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-11-12
Journal Detail:
Title:  Leukemia research     Volume:  33     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-04-06     Completed Date:  2009-04-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  779-87     Citation Subset:  IM    
Institute of Internal Medicine, University of Bergen, Bergen, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Blood Cell Count*
Drug Therapy, Combination
Leukemia, Myeloid, Acute / blood*
Middle Aged
Neoplasm Proteins / blood
Proteoglycans / blood
Risk Factors
Survival Analysis
Theophylline / administration & dosage,  therapeutic use*
Tretinoin / administration & dosage,  therapeutic use*
Valproic Acid / administration & dosage,  therapeutic use*
Reg. No./Substance:
0/ESM1 protein, human; 0/Neoplasm Proteins; 0/Proteoglycans; 302-79-4/Tretinoin; 58-55-9/Theophylline; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early gene expression and morphogenesis of the murine chorioallantoic placenta in vivo and in vitro.
Next Document:  Contextual risk and child psychopathology.